Life Biosciences: First patient dosed in Phase 1 trial of ER-100
ER-100 First Patient Dosed: What Partial Epigenetic Reprogramming Means for Longevity Clinics
Life Biosciences has dosed the first participant in its ER-100 Phase 1 trial, moving partial epigenetic reprogramming from FDA clearance to active human testing.